Ho Jong Yoon

USPTO Granted Patents = 8 (Patent Applications = 1)

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 5.9

ph-index = 2

Forward Citations = 23(Granted Patents)

Company Filing History:

8 out of 2,164

Korea Institute of Science and Technology

patents

1 out of 7

Daegu-gyeongbuk Medical Innovation Foundation

patents

1 out of 1,109

Industry-university Cooperation Foundation Hanyang University

patents

where one patent can have more than one assignee

Years Active: 2014-2019

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10494346 - Substituted pyrimidine-4-carboxylic acids having anticancer activity (2019-12-03),

2. 10442796 - 2,3,5-substituted thiophene compound as protein kinase inhibitor (2019-10-15),

3. 10155767 - Therapeutic agent of acute myeloid leukemia containing 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-D]pyrimidine-2(1H)-one derivatives (2018-12-18),

4. 10130631 - CML therapeutic agents with reduced drug-resistance and side-effect comprising 1,6-disubstituted indole compounds (2018-11-20),

5. 10059717 - Urea compounds containing 3,4-dihydropyrimido[4,5-D]pyrimidin-2(1H)-one skeleton as protein kinase inhibitors (2018-08-28),

6. 10040803 - 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors (2018-08-07),

7. 9586936 - Heteroarylamine derivatives as protein kinase inhibitors (2017-03-07),

8. 8871950 - Process for preparing (+)-polyoxamic acid (2014-10-28),

Title: Ho Jong Yoon: Innovator in Anticancer Compounds

Introduction

Ho Jong Yoon is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of medicinal chemistry, particularly in the development of anticancer agents. With a total of 8 patents to his name, Yoon's work focuses on innovative compounds that have the potential to treat and prevent tumor diseases.

Latest Patents

Among his latest patents, Yoon has developed a novel pyrimidine-4-carboxylic acid derivative that exhibits anticancer activity. This compound is particularly useful as a drug for treating and preventing tumor diseases. Additionally, he has created a 2,3,5-substituted thiophene compound that acts as a protein kinase inhibitor. This compound not only demonstrates inhibitory activity against kinases but also serves as an active ingredient in anticancer agents.

Career Highlights

Ho Jong Yoon has worked with esteemed organizations such as the Korea Institute of Science and Technology and the Daegu-Gyeongbuk Medical Innovation Foundation. His research and innovations have positioned him as a key figure in the development of new therapeutic agents.

Collaborations

Yoon has collaborated with notable colleagues, including Tae Bo Sim and Woo Young Hur, contributing to the advancement of research in his field.

Conclusion

Ho Jong Yoon's innovative work in developing anticancer compounds showcases his dedication to improving medical treatments. His contributions are vital in the ongoing fight against cancer, and his patents reflect a commitment to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.